Atai Life Sciences N.V.
ATAI
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a choā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.18
Price0.00%
$0.00
1Y
Price
Market Cap
$2.656b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-3104.3%
EBITDA Margin-3121.8%
Net Profit Margin-2210.7%
Free Cash Flow Margin-3104.3%
EBITDA Margin-3121.8%
Net Profit Margin-2210.7%
Free Cash Flow MarginRevenue
$3.488m
-14.7%
1y CAGR+403.7%
3y CAGR+311.4%
5y CAGREarnings
-$663.398m
-0.5%
1y CAGR-204.6%
3y CAGR-135.0%
5y CAGREPS
-$3.00
-3.1%
1y CAGR-162.7%
3y CAGR-103.4%
5y CAGRBook Value
$198.779m
$264.877m
Assets$66.098m
Liabilities$2m
DebtDebt to Assets
0.8%
-
Debt to EBITDAFree Cash Flow
-$117.189m
-13.1%
1y CAGR-12.0%
3y CAGR-4.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company